Israel Englander Biomarin Pharmaceutical Inc Call Options Transaction History

Millennium Management LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $3.09 Million - $4.2 Million	44,800 Added 94.92%	92,000 $6.47 Million
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $21.5 Million - $26.7 Million	-289,100 Reduced 85.96%	47,200 $3.89 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $15.9 Million - $18.8 Million	190,100 Added 130.03%	336,300 $29.4 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $9.62 Million - $12.4 Million	126,200 Added 631.0%	146,200 $14.1 Million
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $4.79 Million - $5.55 Million	-55,300 Reduced 73.44%	20,000 $1.73 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $6.61 Million - $8.83 Million	75,300 New	75,300 $7.32 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $821,600 - $969,400	10,000 New	10,000 $848,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.